Related Technologies: N/A.
Product Type: Therapeutic.
Therapeutic Area(s): Oncology | Immunology.
Development Stage: Pre-clinical (*in vivo* validation).
Publications:
• Tiwary S. Endogenously high Omega-3 levels lead to a less suppressive tumor microenvironment. *https://doi.org/10.4049/jimmunol.210.Supp.172.18.*
• Tiwary, S., K. Hsu, K.C. Goldfarbmuren, Z. Xia, and J.A. Berzofsky. High levels of endogenous omega-3 fatty acids prolong the lifespan, promote antigen presentation, and improve DC-based cancer vaccine efficacy in mice. 2025. *Cancer Immunology Research,* in press.
Patents: PCT/US2024/049057, filed September 27, 2024.
Potential Commercial Applications:
• Cancer immunotherapy.
• Development of human DC vaccines.
• Formulations involving omega-3 fatty acids or pro-resolving lipids.
Competitive Advantages:
• Production of DCs with enhanced antigen-presenting function, anti-tumor efficacy and potency.
• Significant tumor reduction and improved survival compared in animals compared with wild-type DCs Potentially clinically safer than classic IMiDs by lower risk of fetal malformations.
Collaboration Opportunity: Researchers at the NCI seek licensing and/or co-development research collaborations for the development of NCI's compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines by using omega-3 fatty acids or pro-resolving lipid mediators.

Dated: June 23, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026–12842 Filed 6–24–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government Owned Inventions Available for License: C8166–45 Cell Line

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute (NCI) seeks licensees for a human T-cell line, C8166–45, transformed by HTLV–1. C8166–45, also known as C63/CRII–2, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth.

FOR FURTHER INFORMATION CONTACT: Inquiries related to this license opportunity should be directed to: Diptadip Dattaroy, Ph.D., Technology Transfer Manager, NCI, Technology Transfer Center, Email: *diptadip.dattaroy@nih.gov* or Phone: 240–276–7092.

SUPPLEMENTARY INFORMATION: Human T-cell leukemia virus type 1 (HTLV–1) was the first human retrovirus reported and is recognized as an etiological agent of adult T-cell leukemia (ATL). However, only a small percentage of individuals develop symptomatic ATL which carries a poor prognosis. The latency period can last for decades and universal screening for HTLV–1 infection has ceased. Thus, the C8166–45 cell line is a necessary component for understanding the mechanisms of HTLV–1 infection and improving clinical outcomes.

NCI researchers derived C8166–45 by cocultivation or fusion of umbilical cord blood lymphocyte with T-cells cultures from leukemia-lymphoma patients. It is highly permissive to HIV–1 infection and characterized for its suitability in replication-competent lentiviral (RCL) assays to assess its safety for gene therapy products, such as lentiviral vectors. This cell line is highly useful in studying viral protein interactions, immortalization of human T-cells, and HIV replication.

''This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses.''
NIH Reference Number: E–272–2007.
Related Technologies: N/A.
Product Type: Research Material/Tool.
Therapeutic Area(s): Infectious Disease | Oncology.
Development Stage: Fully developed.
Publications:
• Salahuddin SZ, et al. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. (PMID 6412453).
• Cornetta K, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. (PMID *28970045*).
Patents: N/A.
Potential Commercial Applications:
• Investigation of HTLV pathogenesis and replication.
• Studies of virus-induced T-cell transformation.
• Studies of HTLV expression regulation by human T-cells.
• Studies of HIV replication.
Competitive Advantages:
• Contains a low amount of viral proteins.
• Does not release detectable virus particles.
• Suitable for testing RCL assay sensitivity.
Collaboration Opportunity: NCI is seeking parties to non-exclusively license the C8166–45 cell line.

Dated: June 23, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026–12843 Filed 6–24–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, Members Conflict-Neurosensory Systems, July 10, 2026, 09:30 a.m. to July 10, 2026, 04:30 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda MD, 20892 which was published in the **Federal Register** on June 09, 2026, 91 FR 34827, Doc. No. 2026–11503.

This meeting is being amended to change the contact person from Kaushik Ray to Eric Tucker, Ph.D., Scientific Review Officer, Center for Scientific Review, NIH, 6701 Rockledge Drive, Bethesda, MD 20892, Ph. (301) 827–0799. The meeting is closed to the public.

Dated: June 22, 2026.

Sterlyn H. Gibson,

Program Specialist, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–12772 Filed 6–24–26; 8:45 am]

BILLING CODE 4167–05–P

INTERNATIONAL TRADE COMMISSION

Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has received a complaint entitled *Certain Adjustable Child*

Carriers and Components Thereof, DN 3917; the Commission is soliciting comments on any public interest issues raised by the complaint or complainant's filing pursuant to the Commission's Rules of Practice and Procedure.

FOR FURTHER INFORMATION CONTACT: Lisa R. Barton, Secretary to the Commission, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2000. The public version of the complaint can be accessed on the Commission's Electronic Document Information System (EDIS) at *https://edis.usitc.gov*. For help accessing EDIS, please email *EDIS3Help@usitc.gov*.

General information concerning the Commission may also be obtained by accessing its internet server at United States International Trade Commission (USITC) at *https://www.usitc.gov*. The public record for this investigation may be viewed on the Commission's Electronic Document Information System (EDIS) at *https://edis.usitc.gov*. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205–1810.

SUPPLEMENTARY INFORMATION: The Commission has received a complaint and a submission pursuant to § 210.8(b) of the Commission's Rules of Practice and Procedure filed on behalf of The Ergobaby Carrier, Inc. on June 22, 2026. The complaint alleges violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain adjustable child carriers and components thereof. The complaint names as respondents: Mabe, LLC of Shelley, ID; Quanzhou Baby Nice Infant and Child Products Co., Ltd. of China; Xiamen Funwhale Technology LLC of China; Xiamen New Baby Products Co., Ltd. of China; Koi Trading Services of Diamond Bar, CA; Portier USA, LLC of Los Angeles, CA; Ava & Oliver of Honolulu, HI; Artipoppe B.V. of Netherlands; Bugaboo Xiamen Industrial Co. Ltd. of China; Bugaboo International B.V. of Netherlands; and Bugaboo North America, Inc. of New York, NY. The complainant requests that the Commission issue a limited exclusion order, cease and desist orders, and impose a bond upon respondents' alleged infringing articles during the 60-day Presidential review period pursuant to 19 U.S.C. 1337(j).

Proposed respondents, other interested parties, members of the public, and interested government agencies are invited to file comments on any public interest issues raised by the complaint or § 210.8(b) filing. Comments should address whether issuance of the relief specifically requested by the complainant in this investigation would affect the public health and welfare in the United States, competitive conditions in the United States economy, the production of like or directly competitive articles in the United States, or United States consumers.

In particular, the Commission is interested in comments that:

(i) explain how the articles potentially subject to the requested remedial orders are used in the United States;

(ii) identify any public health, safety, or welfare concerns in the United States relating to the requested remedial orders;

(iii) identify like or directly competitive articles that complainant, its licensees, or third parties make in the United States which could replace the subject articles if they were to be excluded;

(iv) indicate whether complainant, complainant's licensees, and/or third party suppliers have the capacity to replace the volume of articles potentially subject to the requested exclusion order and/or a cease and desist order within a commercially reasonable time; and

(v) explain how the requested remedial orders would impact United States consumers.

Written submissions on the public interest must be filed no later than by close of business, eight calendar days after the date of publication of this notice in the **Federal Register**. There will be further opportunities for comment on the public interest after the issuance of any final initial determination in this investigation. Any written submissions on other issues must also be filed by no later than the close of business, eight calendar days after publication of this notice in the **Federal Register**. Complainant may file replies to any written submissions no later than three calendar days after the date on which any initial submissions were due, notwithstanding § 201.14(a) of the Commission's Rules of Practice and Procedure. No other submissions will be accepted, unless requested by the Commission. Any submissions and replies filed in response to this Notice are limited to five (5) pages in length, inclusive of attachments.

Persons filing written submissions must file the original document electronically on or before the deadlines stated above. Submissions should refer to the docket number (''Docket No. 3917'') in a prominent place on the cover page and/or the first page. (*See* Handbook for Electronic Filing Procedures, Electronic Filing Procedures [1]). Please note the Secretary's Office will accept only electronic filings unless an exemption is granted. Filings must be made through the Commission's Electronic Document Information System (EDIS, *https://edis.usitc.gov*.) Persons with questions regarding filing should contact the Secretary at *EDIS3Help@usitc.gov*.

Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. *See* 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this Investigation may be disclosed to and used: (i) by the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel,[2] solely for cybersecurity purposes. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.[3]

This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of §§ 201.10 and 210.8(c) of the Commission's Rules of Practice and Procedure (19 CFR 201.10, 210.8(c)).

By order of the Commission.

Issued: June 22, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026–12768 Filed 6–24–26; 8:45 am]

BILLING CODE 7020–02–P

[1] Handbook for Electronic Filing Procedures: *https://www.usitc.gov/secretary/documents/handbook_on_filing_procedures.pdf*.

[2] All contract personnel will sign appropriate nondisclosure agreements.

[3] Electronic Document Information System (EDIS): *https://edis.usitc.gov*.